Back
#1
22.9%
Top 2%
12.2%
Top 10%
9.3%
Top 2%
6.6%
Top 74%
6.1%
Top 4%
6.1%
Top 1%
4.0%
Top 2%
2.9%
Top 7%
2.2%
Top 1%
2.0%
Top 79%
2.0%
Top 2%
2.0%
Top 8%
1.6%
Top 6%
1.4%
Top 2%
1.2%
Top 3%
1.2%
Top 1%
1.0%
Top 11%
1.0%
Top 10%
0.7%
Top 4%
0.7%
Top 6%
0.7%
Top 66%
0.7%
A Phase I Study of ASTX727 plus Talazoparib in Patients with Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
2025-09-12
oncology
Title + abstract only
View on medRxiv
Show abstract
BackgroundPoly (ADP-ribose) polymerase inhibitors (PARPi) are effective in patients with germline BRCA 1/2 and PALB2 mutations but have been largely ineffective as monotherapy in others. PARP interacts with, and is recruited to, DNA damage sites along with epigenetic factors, such as DNA methyltransferase 1 (DNMT1). In addition to increasing PARP-trapping, inhibitors of DNMT modulate ROS-cAMP/PKA signaling and induce a pathogen mimicry, inflammasome signaling response and a BRCAness phenotype t...
Predicted journal destinations
1
Clinical Cancer Research
22 training papers
2
Cancers
57 training papers
3
Nature Communications
483 training papers
4
Frontiers in Oncology
34 training papers
5
PLOS ONE
1737 training papers
6
eLife
262 training papers
7
British Journal of Cancer
22 training papers
8
Cancer Medicine
17 training papers
9
JAMA Network Open
125 training papers
10
Journal of Clinical Investigation
50 training papers
11
Scientific Reports
701 training papers
12
BMC Cancer
21 training papers
13
Proceedings of the National Academy of Sciences
100 training papers
14
iScience
74 training papers
15
Science Translational Medicine
40 training papers
16
Communications Medicine
63 training papers
17
Cell Reports
25 training papers
18
Frontiers in Immunology
140 training papers
19
Nature
58 training papers
20
Communications Biology
36 training papers
21
Cell Reports Medicine
49 training papers
22
BMJ Open
553 training papers